Replies to post #219539 on Biotech Values

[DewDiligence]

ONCE—Steriods were needed (not to control ALT elevations) but to stop loss of expression!

Can you elaborate on this?

[marthambles]

You might want to consider shorting the stock and buying an out of the money call. This would allow you to profit all the way down (minus, of course, the premium paid for the call), while limiting your risk to the difference between the price at which you shorted the stock and the strike price of the call. Obviously, you would have to liquidate your short before your call expired, or roll over the call in order to maintain your protection.

[ghmm]

ONCE:

Today seemed like a good day to go short (my first ever who knows maybe my last ever too :-)). Just a small short position and I bought a few (very small) # of puts yesterday (spread is too big to get a decent amount).

There can be a few good things (from ONCE's perspective) from their Hemophilia A program (Higher factor levels, more consistent individual and within cohort #'s) but with the appreciation in stock price, I think a good part of that seems to be priced in. Probably if BMRN has a serious setback would be a bigger plus for their A program.

On Hemophilia B (which they only have a share of with PFE collaboration) they now seem to be lacking an advantage over Uniqure (time wise and potentially efficacy wise as well). Anyway, I don't intend to hold my short position that long. I see playing QURE vs ONCE Hemophilia B as an argument much further down the road.

The earlier stage pipeline is actually what I find most intriguing from a long investment standpoint (Pompe, CLN2 and Huntington's) and why I would considering going long at much, much lower prices since they are very early still.